Research programme: cyclin-dependent kinase 2 inhibitors - RocheAlternative Names: cyclin-dependent kinase 2 inhibitors research programme - Roche; RO 0182986; RO0282986
Latest Information Update: 19 Sep 2006
At a glance
- Originator Roche
- Mechanism of Action Cyclin-dependent kinase 2 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 19 Sep 2006 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 23 Jul 2003 Preclinical trials in Cancer in USA (unspecified route)